CN104258193B - A kind of pharmaceutical composition for treating neurasthenia and prevention senile dementia - Google Patents
A kind of pharmaceutical composition for treating neurasthenia and prevention senile dementia Download PDFInfo
- Publication number
- CN104258193B CN104258193B CN201410551879.9A CN201410551879A CN104258193B CN 104258193 B CN104258193 B CN 104258193B CN 201410551879 A CN201410551879 A CN 201410551879A CN 104258193 B CN104258193 B CN 104258193B
- Authority
- CN
- China
- Prior art keywords
- ethanol
- fruit
- concentration
- coix seed
- garlic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000024827 Alzheimer disease Diseases 0.000 title claims abstract description 29
- 206010039966 Senile dementia Diseases 0.000 title claims abstract description 26
- 208000007443 Neurasthenia Diseases 0.000 title claims abstract description 19
- 206010003549 asthenia Diseases 0.000 title claims abstract description 19
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 17
- 230000002265 prevention Effects 0.000 title description 2
- 244000077995 Coix lacryma jobi Species 0.000 claims abstract description 50
- 239000000284 extract Substances 0.000 claims abstract description 25
- 150000002596 lactones Chemical class 0.000 claims abstract description 24
- 238000000034 method Methods 0.000 claims abstract description 17
- 239000000463 material Substances 0.000 claims abstract description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 98
- 235000013399 edible fruits Nutrition 0.000 claims description 63
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 50
- 235000013527 bean curd Nutrition 0.000 claims description 43
- 240000002234 Allium sativum Species 0.000 claims description 35
- 235000004611 garlic Nutrition 0.000 claims description 35
- 239000003208 petroleum Substances 0.000 claims description 30
- 239000013078 crystal Substances 0.000 claims description 27
- 239000007788 liquid Substances 0.000 claims description 27
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 22
- 239000000706 filtrate Substances 0.000 claims description 20
- 239000002253 acid Substances 0.000 claims description 18
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 15
- 239000012141 concentrate Substances 0.000 claims description 15
- 238000002390 rotary evaporation Methods 0.000 claims description 15
- 239000000243 solution Substances 0.000 claims description 13
- 229930182470 glycoside Natural products 0.000 claims description 12
- 150000002338 glycosides Chemical class 0.000 claims description 12
- 239000008055 phosphate buffer solution Substances 0.000 claims description 11
- 229920002472 Starch Polymers 0.000 claims description 10
- 239000000469 ethanolic extract Substances 0.000 claims description 10
- 239000011347 resin Substances 0.000 claims description 10
- 229920005989 resin Polymers 0.000 claims description 10
- 239000000741 silica gel Substances 0.000 claims description 10
- 229910002027 silica gel Inorganic materials 0.000 claims description 10
- 239000008107 starch Substances 0.000 claims description 10
- 235000019698 starch Nutrition 0.000 claims description 10
- 238000003756 stirring Methods 0.000 claims description 10
- 239000006228 supernatant Substances 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- JDLKFOPOAOFWQN-VIFPVBQESA-N Allicin Natural products C=CCS[S@](=O)CC=C JDLKFOPOAOFWQN-VIFPVBQESA-N 0.000 claims description 9
- JDLKFOPOAOFWQN-UHFFFAOYSA-N allicin Chemical compound C=CCSS(=O)CC=C JDLKFOPOAOFWQN-UHFFFAOYSA-N 0.000 claims description 9
- 235000010081 allicin Nutrition 0.000 claims description 9
- 238000010828 elution Methods 0.000 claims description 7
- 102000004169 proteins and genes Human genes 0.000 claims description 7
- 108090000623 proteins and genes Proteins 0.000 claims description 7
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 6
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 5
- 229920001353 Dextrin Polymers 0.000 claims description 5
- 239000004375 Dextrin Substances 0.000 claims description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 5
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 5
- 235000019425 dextrin Nutrition 0.000 claims description 5
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 5
- 210000002615 epidermis Anatomy 0.000 claims description 5
- SRCZQMGIVIYBBJ-UHFFFAOYSA-N ethoxyethane;ethyl acetate Chemical compound CCOCC.CCOC(C)=O SRCZQMGIVIYBBJ-UHFFFAOYSA-N 0.000 claims description 5
- 150000004676 glycans Chemical class 0.000 claims description 5
- 239000012535 impurity Substances 0.000 claims description 5
- 239000008101 lactose Substances 0.000 claims description 5
- 230000014759 maintenance of location Effects 0.000 claims description 5
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 5
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 5
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 5
- 239000002245 particle Substances 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 229920001282 polysaccharide Polymers 0.000 claims description 5
- 239000005017 polysaccharide Substances 0.000 claims description 5
- 238000004062 sedimentation Methods 0.000 claims description 5
- 238000010898 silica gel chromatography Methods 0.000 claims description 5
- 238000002791 soaking Methods 0.000 claims description 5
- 229910052708 sodium Inorganic materials 0.000 claims description 5
- 239000011734 sodium Substances 0.000 claims description 5
- 238000013517 stratification Methods 0.000 claims description 5
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 4
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 4
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 4
- 230000001537 neural effect Effects 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 230000006920 protein precipitation Effects 0.000 claims description 4
- 239000001569 carbon dioxide Substances 0.000 claims description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 claims description 3
- 238000000746 purification Methods 0.000 claims description 3
- 238000000926 separation method Methods 0.000 claims description 3
- SWLVFNYSXGMGBS-UHFFFAOYSA-N ammonium bromide Chemical compound [NH4+].[Br-] SWLVFNYSXGMGBS-UHFFFAOYSA-N 0.000 claims description 2
- 229940101309 nervine Drugs 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims 1
- XONPDZSGENTBNJ-UHFFFAOYSA-N molecular hydrogen;sodium Chemical compound [Na].[H][H] XONPDZSGENTBNJ-UHFFFAOYSA-N 0.000 claims 1
- 241000196324 Embryophyta Species 0.000 abstract description 15
- 239000003814 drug Substances 0.000 abstract description 12
- 239000000203 mixture Substances 0.000 abstract description 11
- 239000000126 substance Substances 0.000 abstract description 8
- 238000000605 extraction Methods 0.000 abstract description 7
- 239000002994 raw material Substances 0.000 abstract description 7
- 239000004480 active ingredient Substances 0.000 abstract description 5
- 229940079593 drug Drugs 0.000 abstract description 5
- 206010028980 Neoplasm Diseases 0.000 abstract description 4
- 201000011510 cancer Diseases 0.000 abstract description 4
- 238000002360 preparation method Methods 0.000 abstract description 3
- 230000035755 proliferation Effects 0.000 abstract description 3
- 230000032683 aging Effects 0.000 abstract description 2
- 238000009776 industrial production Methods 0.000 abstract description 2
- 239000000419 plant extract Substances 0.000 abstract description 2
- 230000008569 process Effects 0.000 abstract description 2
- 230000004622 sleep time Effects 0.000 abstract description 2
- 229940126680 traditional chinese medicines Drugs 0.000 abstract description 2
- GWHCXVQVJPWHRF-UHFFFAOYSA-N cis-tetracosenoic acid Natural products CCCCCCCCC=CCCCCCCCCCCCCCC(O)=O GWHCXVQVJPWHRF-UHFFFAOYSA-N 0.000 description 26
- GWHCXVQVJPWHRF-KTKRTIGZSA-N (15Z)-tetracosenoic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCCCC(O)=O GWHCXVQVJPWHRF-KTKRTIGZSA-N 0.000 description 25
- XJXROGWVRIJYMO-SJDLZYGOSA-N Nervonic acid Natural products O=C(O)[C@@H](/C=C/CCCCCCCC)CCCCCCCCCCCC XJXROGWVRIJYMO-SJDLZYGOSA-N 0.000 description 25
- 239000003921 oil Substances 0.000 description 21
- 235000019198 oils Nutrition 0.000 description 21
- 229930182478 glucoside Natural products 0.000 description 16
- 150000008131 glucosides Chemical class 0.000 description 16
- 230000000694 effects Effects 0.000 description 14
- 239000000047 product Substances 0.000 description 8
- 241000251730 Chondrichthyes Species 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 239000002775 capsule Substances 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 235000007354 Coix lacryma jobi Nutrition 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 4
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 4
- 235000019799 monosodium phosphate Nutrition 0.000 description 4
- 210000005036 nerve Anatomy 0.000 description 4
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 4
- 238000004809 thin layer chromatography Methods 0.000 description 4
- PUQSUZTXKPLAPR-KSSYENDESA-N 4-(beta-D-Glucopyranosyloxy) benzyl alcohol Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1)c1ccc(CO)cc1 PUQSUZTXKPLAPR-KSSYENDESA-N 0.000 description 3
- 241001279686 Allium moly Species 0.000 description 3
- PUQSUZTXKPLAPR-UJPOAAIJSA-N Gastrodin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(CO)C=C1 PUQSUZTXKPLAPR-UJPOAAIJSA-N 0.000 description 3
- 240000005979 Hordeum vulgare Species 0.000 description 3
- 235000007340 Hordeum vulgare Nutrition 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 229930193974 gastrodin Natural products 0.000 description 3
- PUQSUZTXKPLAPR-NZEXEKPDSA-N helicidol Natural products O([C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](CO)O1)c1ccc(CO)cc1 PUQSUZTXKPLAPR-NZEXEKPDSA-N 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- DPQCZNIGGNJGTD-UHFFFAOYSA-N Chloride-(??)-2-Methylpentanoic acid Natural products CCCCCCC=CCCCCCCCCCC(=O)OC(C)C(C)OC(=O)CCCCCCCC=CCCCCCC DPQCZNIGGNJGTD-UHFFFAOYSA-N 0.000 description 2
- DPQCZNIGGNJGTD-MVCBGFDASA-N Coixenolide Chemical compound CCCCCC\C=C\CCCCCCCCCC(=O)O[C@@H](C)[C@@H](C)OC(=O)CCCCCCC\C=C/CCCCCC DPQCZNIGGNJGTD-MVCBGFDASA-N 0.000 description 2
- 241000209504 Poaceae Species 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 210000005013 brain tissue Anatomy 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000004126 nerve fiber Anatomy 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 235000017807 phytochemicals Nutrition 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229930000223 plant secondary metabolite Natural products 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000003815 supercritical carbon dioxide extraction Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- OLZAGZCCJJBKNZ-UJPOAAIJSA-N 4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxybenzaldehyde Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(C=O)C=C1 OLZAGZCCJJBKNZ-UJPOAAIJSA-N 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000024806 Brain atrophy Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000928581 Malania Species 0.000 description 1
- 241000928579 Malania oleifera Species 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010029333 Neurosis Diseases 0.000 description 1
- 241000221014 Olacaceae Species 0.000 description 1
- 244000088415 Raphanus sativus Species 0.000 description 1
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 206010008129 cerebral palsy Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N formaldehyde Substances O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- OLZAGZCCJJBKNZ-UHFFFAOYSA-N formaldehydephenlyl-O-beta-D-pyranosyl alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(C=O)C=C1 OLZAGZCCJJBKNZ-UHFFFAOYSA-N 0.000 description 1
- 235000020351 fruit smoothie Nutrition 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- ALHUZKCOMYUFRB-UHFFFAOYSA-N muskone Natural products CC1CCCCCCCCCCCCC(=O)C1 ALHUZKCOMYUFRB-UHFFFAOYSA-N 0.000 description 1
- 230000005709 nerve cell growth Effects 0.000 description 1
- 230000030363 nerve development Effects 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 208000015238 neurotic disease Diseases 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 235000013570 smoothie Nutrition 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- -1 that is Chemical compound 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
- A61K36/8994—Coix (Job's tears)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/54—Improvements relating to the production of bulk chemicals using solvents, e.g. supercritical solvents or ionic liquids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Molecular Biology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开一种治疗神经衰弱和预防老年痴呆症的药物组合物,由下列质量百分比的组分组成:蒜头果神经酸1~10%、豆腐果苷1~10%、薏苡仁内酯1~10%、余量为辅料。本发明提供的药物有助于老年人的睡眠时间的延长,薏苡仁内酯能防癌抑制多种癌细胞增殖,三者合用能有效防止和控制老年痴呆症的发生和治愈,给老龄化越来越严重的全世界带来一种纯植物萃取的安全有效的植物组合物。本发明采用的组方配伍合理,原料均来自天然植物,同时本发明提供的中药组合物的制备方法,可操作性强,尤其是根据各味中药有效成分化学性质涉及提取工艺,所得提取物有效成分含量高,具有药效高、临床用量少等优点,且工艺稳定,适合工业大生产。The invention discloses a pharmaceutical composition for treating neurasthenia and preventing senile dementia. 10%, and the balance is auxiliary materials. The medicine provided by the invention is helpful for the prolongation of the sleep time of the elderly, coix seed lactone can prevent cancer and inhibit the proliferation of various cancer cells, and the combination of the three can effectively prevent and control the occurrence and cure of senile dementia, and give the aging more More and more serious world brings a safe and effective botanical composition of pure plant extracts. The prescriptions adopted in the present invention have reasonable compatibility, and the raw materials are all from natural plants. At the same time, the preparation method of the traditional Chinese medicine composition provided by the present invention has strong operability, especially according to the extraction process related to the chemical properties of the active ingredients of various traditional Chinese medicines, the obtained extracts are effective. The composition content is high, and it has the advantages of high drug efficacy, less clinical dosage, etc., and the process is stable, which is suitable for large-scale industrial production.
Description
技术领域technical field
本发明属于生物医药技术领域,涉及一种治疗神经衰弱和预防老年痴呆症的药物组合物。The invention belongs to the technical field of biomedicine and relates to a pharmaceutical composition for treating neurasthenia and preventing senile dementia.
背景技术Background technique
随着我国经济的发展,以及人口政策的实施,我国人口的年龄结构发生了很大的转变。中国的预期寿命从1990年的68.4岁上升到2008年的73.8岁,老年人口占总人口的比重越来越大,根据经济合作与发展组织提供的数据,与中国的总人口相对而言,估计超过65岁的人口比率将从2005年的7.8%上升到2030年的16.3%。With the development of my country's economy and the implementation of population policy, the age structure of my country's population has undergone great changes. China's life expectancy rose from 68.4 years in 1990 to 73.8 years in 2008, and the proportion of the elderly population in the total population is increasing. According to the data provided by the Organization for Economic Cooperation and Development, relative to China's total population, it is estimated that The proportion of the population over the age of 65 will rise from 7.8% in 2005 to 16.3% in 2030.
研究人员发现,鲨鱼的脑组织受到重创后,能自动恢复功能,因为鲨鱼的脑组织中含有一种叫“神经酸”的物质,能修复大脑神经信息传递通道——神经纤维,并促使神经细胞再生。如今,神经酸(NA)已经被各国的科学家一直公认为是大脑神经纤维和神经细胞的核心天然有效成分。神经酸还能有效的治疗老年痴呆、脑瘫、脑萎缩、记忆力衰退、失眠健忘等脑部疾病。而人类和鲨鱼不同,人类自身无法合成神经酸,随着年龄增长或脑部受到创伤,都有可能造成神经酸的衰减,导致疾病。The researchers found that after the shark's brain tissue was severely injured, it can automatically recover its function, because the shark's brain tissue contains a substance called "nervous acid", which can repair the nerve information transmission channel of the brain - nerve fibers, and promote nerve cells to recover. regeneration. Today, nervonic acid (NA) has been recognized by scientists from all over the world as the core natural active ingredient of brain nerve fibers and nerve cells. Neural acid can also effectively treat brain diseases such as senile dementia, cerebral palsy, brain atrophy, memory loss, insomnia and forgetfulness. Humans are different from sharks. Humans cannot synthesize nervonic acid by themselves. As they age or the brain is traumatized, it may cause the attenuation of nervonic acid and lead to disease.
从鲨鱼中提取神经酸必须杀死鲨鱼,破坏海洋生态平衡,随着国际组织禁止捕杀鲨鱼的呼声越来越高,欧美等国家都十分重视从植物中挖掘神经酸资源,经研究发现,含有2%以上神经酸的植物有十余种,其中以中国特有单种植物——蒜头果中神经酸含量最高,并且高达62.6%,其开发价值和经济价值巨大,可称为“植物中的黄金果”。Extracting nervonic acid from sharks must kill sharks and destroy the ecological balance of the ocean. With the increasing calls of international organizations to ban the killing of sharks, countries such as Europe and the United States attach great importance to excavating nervonic acid resources from plants. Research has found that it contains 2 There are more than ten kinds of plants with more than 100% nervonic acid, among them, the unique single plant in China - Garlic fruit has the highest nervonic acid content, and it is as high as 62.6%. Its development value and economic value are huge, and it can be called "the golden fruit of plants". ".
蒜头果(Malania oleifera Chun et Lee)是铁青树科(Olacaceae),蒜头果属(Malania)植物。又称山桐果,马兰后。属于国家二级保护植物。在云南的东南部如富宁、广南、文山均有分布。蒜头果的种仁富含丰富的油脂,是合成麝香酮(muscine)的理想原料。蒜头果种子含油量高达50~60%,经皂化后的脂肪酸含有40~50%的二十四碳-15-烯酸,即神经酸,它有助于恢复神经末梢活性,促进神经细胞生长和发育,有抗老年痴呆的作用。Malania oleifera Chun et Lee is a plant of the genus Malania in the Olacaceae family . Also known as Shantong fruit, after Malan. It belongs to the second-class national protected plants. It is distributed in the southeastern part of Yunnan such as Funing, Guangnan and Wenshan. The seed kernel of garlic fruit is rich in oil and is an ideal raw material for the synthesis of muskone (muscine) . The oil content of garlic fruit seeds is as high as 50-60%, and the fatty acid after saponification contains 40-50% tetracos-15-enoic acid, that is, nervonic acid, which helps to restore the activity of nerve endings, promote nerve cell growth and Development, has anti-senile dementia effect.
据统计,现在世界上有2400万痴呆患者。在我国,老年痴呆症的患病人数达500多万,而且每年还有30万的新发病例。老年痴呆症的发病机理以及新药研发正受到世界各国的高度重视。因此,以蒜头果为原料,开发治疗老年痴呆症的食用油、保健品和药物具有广大的市场潜力和医疗价值。According to statistics, there are now 24 million dementia patients in the world. In my country, the number of patients with Alzheimer's disease has reached more than 5 million, and there are 300,000 new cases every year. The pathogenesis of Alzheimer's disease and the research and development of new drugs are being paid great attention by countries all over the world. Therefore, using garlic fruit as a raw material to develop edible oils, health products and medicines for the treatment of senile dementia has great market potential and medical value.
薏苡仁(Coix seed),是禾本科多年生草本植物薏苡(Coix lacryma-jobi L.)的成熟果仁,薏苡仁在我国大部分地区均有出产,由于薏苡的营养价值很高,被誉为世界禾本科植物之王。薏苡仁含有约2.7%左右的薏苡仁油,慧苡仁种仁含蛋白质16.2%,脂肪4.65%,碳水化物79.17%,少量维生素B1。薏苡种子含多种氨基酸(包括亮氨酸、赖氨酸、精氨酸、酪氨酸等)还含有薏苡素、薏苡酯、三萜化合物等物质。薏苡仁中抑制多种肿瘤细胞增殖的有效成份是薏苡酯、薏苡仁内酯,该类化合物还具有增强激素调节功能和促进免疫系统和酶系统的功能,对细胞免疫和体液免疫也有促进作用,大量动物实验和临床证实薏苡仁油有增强免疫力和抗肿瘤作用。薏仁在我国各地都有种植,云南省以曲靖市师宗县为代表,薏仁资源比较丰富,是我国重要的薏仁生区之一。薏苡仁营养丰富,并且具有很好的抗肿瘤、活血化瘀等药用价值,市场上已陆陆续续出现了一些薏苡仁产品,薏仁保健酒、薏仁醋、薏仁粉、薏仁茶等,非常受广大消费者的欢迎。但与国外薏仁的产品相比,国内薏仁产品开发相对不足,薏仁的利用基本还停留在人们的饮食中,深加工产品严重缺乏。 Coix seed is the mature kernel of Coix lacryma-jobi L., a perennial herb of the Poaceae family. Coix seed is produced in most parts of China. Because of its high nutritional value, Coix seed is known as the world's The king of grasses. Coix seed contains about 2.7% of coix seed oil, and Coix seed contains 16.2% protein, 4.65% fat, 79.17% carbohydrate, and a small amount of vitamin B 1 . Coix seed contains a variety of amino acids (including leucine, lysine, arginine, tyrosine, etc.) and also contains coixin, coixin, triterpenoids and other substances. The effective ingredients in coix seed that inhibit the proliferation of various tumor cells are coixin and coixenolactone. These compounds also have the functions of enhancing hormone regulation and promoting the immune system and enzyme system, and can also promote cellular immunity and humoral immunity. A large number of animal experiments and clinics have confirmed that coix seed oil has the effect of enhancing immunity and anti-tumor. Job's tears are planted all over my country. Yunnan Province, represented by Shizong County, Qujing City, has rich resources of Job's tears and is one of the important growing areas of Job's tears in my country. Coix seed is rich in nutrition and has good medicinal value such as anti-tumor, promoting blood circulation and removing blood stasis. Some coix seed products have appeared in the market one after another, such as coix seed health wine, coix seed vinegar, coix seed powder, coix seed tea, etc., which are very popular. The majority of consumers welcome. However, compared with foreign barley products, the development of domestic barley products is relatively insufficient, and the utilization of barley is basically still in people's diet, and there is a serious shortage of deep-processed products.
豆腐果,别称母猪果,豆腐果提取物为豆腐果昔(helicid),对甲醛苯-O-β-D-阿咯吡喃糖苷,又名昆明神衰果素,为云南野生植物山龙眼科萝卜树(Helieiaerra6c:Hook.f)的果实(俗称豆腐渣果),其化学结构类与天麻素相似。药理和临床研究表明,豆腐果昔对中枢神经系统的作用与天麻素相似,但其镇静、止痛作用较天麻素强,对神经官能症引起的头痛、头昏、睡眠障碍的治疗作用显效快,同时对记忆力、思维力具有较好改善和调节作用,应用前景广阔。母猪果主要分布在云南省南部和西南部分地区,以普洱市和红河州分布最多,大多数处于野生状态,亟待人工育种保护和深加工产品的开发利用。Tofu fruit, also known as sow fruit, tofu fruit extract is tofu fruit smoothie (helicid) , p-formaldehyde benzene-O-β-D-allopyranoside, also known as Kunming Shenshuai fruit, is a wild plant in Yunnan The fruit of ophthalmic radish tree (Helieiaerra6c:Hook.f) (commonly known as bean curd fruit), its chemical structure is similar to gastrodin. Pharmacological and clinical studies have shown that the effect of tofu smoothie on the central nervous system is similar to that of gastrodin, but its sedative and analgesic effects are stronger than gastrodin, and its therapeutic effect on headache, dizziness, and sleep disorders caused by neurosis is rapid. At the same time, it has a good improvement and regulation effect on memory and thinking power, and has broad application prospects. Sow fruit is mainly distributed in the south and southwestern parts of Yunnan Province, with the largest distribution in Pu'er City and Honghe Prefecture. Most of them are in a wild state, and they are in urgent need of artificial breeding protection and development and utilization of deep-processed products.
本发明以三种在云南省集中分布或栽培的药用植物为研究对象,采用植物化学提取手段分别从这三种植物中提取预防老年痴呆症、抗抑郁和抗肿瘤的有效成分,并采用药剂学手段制备成中药保健片剂或胶囊剂,为中老年患者提供一种安全有效的中药保健品。The present invention takes three kinds of medicinal plants concentratedly distributed or cultivated in Yunnan Province as the research objects, and uses phytochemical extraction methods to extract the active ingredients of preventing Alzheimer's disease, anti-depression and anti-tumor from these three plants, and uses medicament It is prepared into traditional Chinese medicine health-care tablets or capsules by scientific means, and provides a safe and effective traditional Chinese medicine health-care product for middle-aged and elderly patients.
发明内容Contents of the invention
为解决现有技术中预防老年痴呆症、抗抑郁和抗肿瘤药品的原料难以获得以及目前药品存在副作用等问题,本发明提供一种治疗神经衰弱和预防老年痴呆症的药物组合物,以使用纯植物原料制备抗老年痴呆、神经衰弱、抗肿瘤的药物。In order to solve the problems in the prior art that raw materials for preventing senile dementia, antidepressant and antitumor drugs are difficult to obtain, and current drugs have side effects, the present invention provides a pharmaceutical composition for treating neurasthenia and preventing senile dementia, using pure Plant raw materials are used to prepare anti-senile dementia, neurasthenia and anti-tumor drugs.
本发明通过下列技术方案实现:一种治疗神经衰弱和预防老年痴呆症的药物组合物,其特征在于由下列质量百分比的组分组成:The present invention is achieved through the following technical solutions: a pharmaceutical composition for treating neurasthenia and preventing senile dementia, characterized in that it consists of the following components in mass percentage:
蒜头果神经酸 1~10%、Garlic Neural Acid 1~10%,
豆腐果苷1~10%、Tofu fruit glycosides 1~10%,
薏苡仁内酯 1~10%、Coix seed lactone 1~10%,
余量为辅料。The balance is excipients.
所述辅料包括药学领域常规的糊精、乳糖、羧甲基淀粉钠、微晶纤维素、淀粉、羟丙基纤维素。The auxiliary materials include conventional dextrin, lactose, sodium carboxymethyl starch, microcrystalline cellulose, starch and hydroxypropyl cellulose in the field of pharmacy.
所述蒜头果神经酸按下列步骤进行提取、纯化:Described garlic nervine acid extracts, purifies according to the following steps:
(1)将蒜头果种子去外壳和表皮,按固液比g/mL为1~10:5~50,用3~4℃的浓度为20mM、pH=6.0~7.0的磷酸盐缓冲液进行捣碎后,再经超声波粉碎处理30~50min,于3~4℃下进行抽提过夜,然后过滤,再在3~4℃下以5000~8000 r/min的转速进行离心分离30~40 min,重复两次,去除上清液得剩余物;(1) Remove the shell and epidermis of the garlic seeds, and pound them with a phosphate buffer solution with a concentration of 20mM and a pH of 6.0 to 7.0 at 3 to 4°C according to the solid-to-liquid ratio g/mL of 1 to 10:5 to 50. After being crushed, it was subjected to ultrasonic crushing treatment for 30-50 minutes, extracted at 3-4°C overnight, then filtered, and then centrifuged at 5000-8000 r/min at 3-4°C for 30-40 minutes. Repeat twice, remove the supernatant to get the residue;
(2)将步骤(1)所得剩余物按固液比g/mL=1~5:5~20加入石油醚进行搅拌,再静置分层,经过滤后收集滤液,再以滤液反复浸泡滤渣2-3次,每次浸泡30~60min后过滤,合并滤液,再在40~50℃下进行旋转蒸发以去除石油醚,得到蒜头果油;(2) Add petroleum ether to the residue obtained in step (1) according to the solid-to-liquid ratio g/mL=1~5:5~20 for stirring, then let it stand for stratification, collect the filtrate after filtration, and soak the filter residue repeatedly with the filtrate 2-3 times, filter after soaking for 30-60 minutes each time, combine the filtrates, and then perform rotary evaporation at 40-50°C to remove petroleum ether, and obtain garlic fruit oil;
(3)按上样量:硅胶量=1~10:10~100的质量比称取硅胶G,先按固液比g/mL=1~5:2~10加入石油醚溶解硅胶G,再搅拌20~30min后,将其倒入层析柱中,待硅胶层析柱不含有气泡,沉降稳定后,将步骤(2)所得蒜头果油按固液比g/mL=1~5:1~10加入石油醚溶解后,装入硅胶层析柱上层,采用石油醚-乙酸乙酯洗脱系统进行梯度洗脱,按溶解有蒜头果油的石油醚:乙酸乙酯=50:1~30:1(V/V)的馏分,于40~50℃以下对馏分进行减压浓缩,得到无色块状结晶,即为蒜头果神经酸。(3) Weigh the silica gel G according to the mass ratio of the sample amount: the amount of silica gel = 1 ~ 10: 10 ~ 100, first add petroleum ether to dissolve the silica gel G according to the solid-liquid ratio g/mL = 1 ~ 5: 2 ~ 10, and then After stirring for 20-30 minutes, pour it into the chromatographic column. After the silica gel chromatographic column does not contain air bubbles and the sedimentation is stable, the garlic fruit oil obtained in step (2) is mixed according to the solid-liquid ratio g/mL=1-5:1 ~10 After adding petroleum ether to dissolve, put it into the upper layer of the silica gel chromatography column, and use petroleum ether-ethyl acetate elution system to carry out gradient elution, according to petroleum ether dissolved with garlic fruit oil:ethyl acetate=50:1~30 : 1 (V/V) fraction, the fraction was concentrated under reduced pressure at 40-50°C to obtain colorless blocky crystals, which is allicin.
用薄层色谱法将神经酸标准品与该无色结晶在同一薄层板上点样,展开,进行比对,结果该无色结晶和神经酸标准品在同一薄层板的相同位置显示相同紫的斑点,并且在三种不同展开系统中均具有相同颜色斑点和相同Rf值,证明该无色结晶即为神经酸。此方法得到的神经酸含量大于95%。The nervonic acid standard and the colorless crystal were spotted on the same thin-layer plate by thin-layer chromatography, developed, and compared. As a result, the colorless crystal and the nervonic acid standard showed the same color at the same position on the same thin-layer plate. Purple spots, and the same color spots and the same Rf value in three different unfolding systems, prove that the colorless crystal is nervonic acid. The content of nervous acid obtained by this method is greater than 95%.
所述步骤(1)的磷酸盐缓冲液按下列操作配制:将浓度为0.2M的磷酸氢二钠溶液与浓度为0.2M磷酸二氢钠溶液按体积比为12.3~61:87.7~39混合,即得到pH=6.0~7.0的磷酸盐缓冲液。The phosphate buffer in the step (1) is prepared according to the following operations: mix the disodium hydrogen phosphate solution with a concentration of 0.2M and the sodium dihydrogen phosphate solution with a concentration of 0.2M in a volume ratio of 12.3~61:87.7~39, That is, a phosphate buffer solution with a pH of 6.0 to 7.0 is obtained.
所述步骤(1)的上清液经后续纯化分离得到蛋白质沉淀。The supernatant of the step (1) is subjected to subsequent purification and separation to obtain protein precipitates.
所述步骤(3)的硅胶G的粒度为200~300目。The particle size of the silica gel G in the step (3) is 200-300 mesh.
所述豆腐果苷按下列方法提取纯化,经过下列各步骤:The tofu fruit glycosides are extracted and purified according to the following method, through the following steps:
(1)豆腐果种子粉碎,过100目筛,再加入体积浓度为50~70%的乙醇在20~30℃下冷浸30~60min,再超声波提取30~60min,过滤,滤液在45~55℃下进行旋转蒸发浓缩,回收乙醇,得到母猪果乙醇提取物;(1) Crush the bean curd seeds, pass through a 100-mesh sieve, then add ethanol with a volume concentration of 50-70%, cold-soak at 20-30°C for 30-60 minutes, then ultrasonically extract for 30-60 minutes, filter, and the filtrate is at 45-55 Carry out rotary evaporation and concentration at ℃, recover ethanol, and obtain sow fruit ethanol extract;
(2)在步骤(1)所得豆腐果乙醇提取物中按固液比g/mL为1~5:5~25加入纯水进行溶解,上大孔树脂D101型,先用纯水洗脱除去多糖、蛋白质等水溶性杂质,再用体积浓度为30~50%的乙醇洗脱4~5个保留体积,收集大孔树脂体积浓度为30~50%的乙醇流出液,经减压浓缩,再加入浓缩物体积2~3倍的浓度为90~95%的乙醇,在3~4℃下静置12~24h以析出结晶,再抽滤出结晶,即得到豆腐果苷纯品。所得豆腐果苷纯度大于95%。(2) Add pure water to the tofu fruit ethanol extract obtained in step (1) according to the solid-to-liquid ratio g/mL of 1-5:5-25 to dissolve, apply macroporous resin D101 type, and first elute with pure water to remove Water-soluble impurities such as polysaccharides and proteins, and then elute 4 to 5 retention volumes with ethanol with a volume concentration of 30 to 50%, collect the ethanol effluent with a volume concentration of 30 to 50% of the macroporous resin, concentrate under reduced pressure, and then Add 90-95% ethanol with a concentration of 2-3 times the volume of the concentrate, let stand at 3-4°C for 12-24 hours to precipitate crystals, and then filter out the crystals to obtain pure tofu fruit glycosides. The purity of the obtained tofu fruit glycosides is greater than 95%.
所述薏苡仁内酯按下列方法提取纯化,经过下列各步骤:The coix seed lactone is extracted and purified according to the following method, through the following steps:
将薏苡仁粉碎,过100目筛,再将薏苡仁粉在温度35~40℃、压力37~40MPa、CO2流量为10~20kg/h的条件下进行超临界二氧化碳萃取1~2h,采用体积浓度为70~95%的乙醇溶解萃取物质,再经旋转蒸发去除乙醇,得到黄色的油脂,即为薏苡仁内酯。Crush coix seed, pass through a 100-mesh sieve, and then extract coix seed powder with supercritical carbon dioxide for 1-2 hours at a temperature of 35-40°C, a pressure of 37-40 MPa, and a CO flow rate of 10-20 kg/h. Dissolve the extract in ethanol with a concentration of 70-95%, and then remove the ethanol by rotary evaporation to obtain yellow oil, which is coix seed lactone.
上述蒜头果神经酸、豆腐果苷、薏苡仁内酯提取物按比例充分混合,再加入药学上可接受的辅料制备成任何一种常用的口服制剂,如胶囊剂、颗粒剂、口服液、丸剂或片剂。The above-mentioned garlic fruit nervonic acid, tofu glucoside, and coix seed lactone extracts are fully mixed in proportion, and then added with pharmaceutically acceptable auxiliary materials to prepare any commonly used oral preparations, such as capsules, granules, oral liquids, and pills or tablet.
本发明具备的优点和效果:本发明提供的药物主要为脂肪酸、内酯等小分子化合物的组合体,通过植物化学提取手段,从云南特有和大面积种植的几种植物中提取有效成分,其中神经酸具有显著的抗老年痴呆症的作用,豆腐果苷能舒缓老年痴呆患者焦虑紧张的情绪,有助于老年人的睡眠时间的延长,薏苡仁内酯能防癌抑制多种癌细胞增殖,三者合用能有效防止和控制老年痴呆症的发生和治愈,给老龄化越来越严重的全世界带来一种纯植物萃取的安全有效的植物组合物。本发明采用的组方配伍合理,原料均来自天然植物,同时本发明提供的中药组合物的制备方法,可操作性强,尤其是根据各味中药有效成分化学性质涉及提取工艺,所得提取物有效成分含量高,具有药效高、临床用量少等优点,且工艺稳定,适合工业大生产。The advantages and effects of the present invention: the medicine provided by the present invention is mainly a combination of small molecular compounds such as fatty acids and lactones. Through phytochemical extraction methods, active ingredients are extracted from several plants that are unique to Yunnan and grown in large areas. Among them Nervous acid has a significant anti-senile dementia effect. Tofu fruit glycosides can relieve the anxiety and tension of senile dementia patients and help the elderly to prolong their sleep time. Coix seed lactone can prevent cancer and inhibit the proliferation of various cancer cells. The combination of the three can effectively prevent and control the occurrence and cure of senile dementia, and bring a safe and effective plant composition of pure plant extracts to the world where the aging is getting worse. The prescriptions adopted in the present invention have reasonable compatibility, and the raw materials are all from natural plants. At the same time, the preparation method of the traditional Chinese medicine composition provided by the present invention has strong operability, especially according to the extraction process related to the chemical properties of the active ingredients of various traditional Chinese medicines, the obtained extracts are effective. The composition content is high, and it has the advantages of high drug efficacy, less clinical dosage, etc., and the process is stable, which is suitable for large-scale industrial production.
具体实施方式detailed description
以下通过实施例来进一步说明本发明。The present invention is further illustrated below by way of examples.
实施例1Example 1
治疗神经衰弱和预防老年痴呆症的药物组合物,由下列质量百分比的组分组成:The pharmaceutical composition for treating neurasthenia and preventing senile dementia consists of the following components in mass percentage:
蒜头果神经酸 2%、Garlic Neural Acid 2%,
豆腐果苷6%、Tofu fruit glycosides 6%,
薏苡仁内酯 5%、Coixenolide 5%,
辅料 87%,Excipients 87%,
其中辅料为糊精、乳糖、羧甲基淀粉钠、微晶纤维素、淀粉。The auxiliary materials are dextrin, lactose, sodium carboxymethyl starch, microcrystalline cellulose, and starch.
其中蒜头果神经酸按下列步骤进行提取、纯化:Wherein the garlic fruit nerve acid is extracted and purified according to the following steps:
(1)将蒜头果种子去外壳和表皮,按固液比g/mL为10:50,用4℃的浓度为20mM、pH=6.0的磷酸盐缓冲液进行捣碎后,再经超声波粉碎处理40min,于3℃下进行抽提过夜,然后用4层纱布过滤,再在3℃下以6000 r/min的转速进行离心分离40 min,重复两次,去除上清液得剩余物;其中磷酸盐缓冲液按下列操作配制:将浓度为0.2M的磷酸氢二钠溶液与浓度为0.2M磷酸二氢钠溶液按体积比为61:39混合,即得到pH=7.0的磷酸盐缓冲液;上清液经后续纯化分离得到蛋白质沉淀;(1) Remove the shell and epidermis of the garlic fruit seeds, according to the solid-liquid ratio g/mL of 10:50, mash with phosphate buffer solution with a concentration of 20mM and pH=6.0 at 4°C, and then ultrasonically pulverize 40min, extract overnight at 3°C, then filter with 4 layers of gauze, then centrifuge at 6000 r/min for 40min at 3°C, repeat twice, remove the supernatant to obtain the residue; The salt buffer solution is prepared according to the following operations: mix the disodium hydrogen phosphate solution with a concentration of 0.2M and the sodium dihydrogen phosphate solution with a concentration of 0.2M at a volume ratio of 61:39 to obtain a phosphate buffer solution with pH=7.0; The supernatant is purified and separated to obtain protein precipitation;
(2)将步骤(1)所得剩余物按固液比g/mL=3:20加入石油醚进行搅拌,再静置分层,经过滤后收集滤液,再以滤液反复浸泡滤渣3次,每次浸泡50min后过滤,合并滤液,再在40℃下进行旋转蒸发以去除石油醚,得到淡黄色的蒜头果油;(2) Add petroleum ether to the residue obtained in step (1) according to the solid-to-liquid ratio g/mL=3:20 for stirring, then let it stand for stratification, collect the filtrate after filtration, and then soak the filter residue 3 times with the filtrate repeatedly, each Filter after soaking for 50 minutes for the first time, combine the filtrates, and then carry out rotary evaporation at 40°C to remove petroleum ether to obtain light yellow garlic fruit oil;
(3)按上样量:硅胶量=5:60的质量比称取粒度为300目的硅胶G,先按固液比g/mL=3:8加入石油醚溶解硅胶G,再搅拌25min后,将其倒入层析柱中,待硅胶层析柱不含有气泡,沉降稳定后,将步骤(2)所得蒜头果油按固液比g/mL=5:10加入石油醚溶解后,装入硅胶层析柱上层,采用石油醚-乙酸乙酯洗脱系统进行梯度洗脱,按溶解有蒜头果油的石油醚:乙酸乙酯=40:1(V/V)的馏分,于50℃以下对馏分进行减压浓缩,得到无色块状结晶,即为蒜头果神经酸。(3) Weigh the silica gel G with a particle size of 300 mesh according to the mass ratio of sample amount: silica gel amount = 5:60, first add petroleum ether to dissolve the silica gel G according to the solid-liquid ratio g/mL=3:8, and then stir for 25 minutes. Pour it into the chromatographic column. After the silica gel chromatographic column does not contain air bubbles and the sedimentation is stable, the garlic fruit oil obtained in step (2) is dissolved in petroleum ether according to the solid-to-liquid ratio g/mL=5:10, and then put into The upper layer of the silica gel chromatography column is gradiently eluted with petroleum ether-ethyl acetate elution system, according to the fraction of petroleum ether dissolved with garlic fruit oil:ethyl acetate=40:1 (V/V), at below 50°C Concentrate the fractions under reduced pressure to obtain colorless blocky crystals, which are allicin.
用薄层色谱法将神经酸标准品与该无色结晶在同一薄层板上点样,展开,进行比对,结果该无色结晶和神经酸标准品在同一薄层板的相同位置显示相同紫的斑点,并且在三种不同展开系统中均具有相同颜色斑点和相同Rf值,证明该无色结晶即为神经酸。此方法得到的神经酸含量大于95%。神经酸得率为蒜头果油的10.462%。The nervonic acid standard and the colorless crystal were spotted on the same thin-layer plate by thin-layer chromatography, developed, and compared. As a result, the colorless crystal and the nervonic acid standard showed the same color at the same position on the same thin-layer plate. Purple spots, and the same color spots and the same Rf value in three different unfolding systems, prove that the colorless crystal is nervonic acid. The content of nervous acid obtained by this method is greater than 95%. The yield of nervonic acid is 10.462% of that of garlic fruit oil.
其中豆腐果苷按下列方法提取纯化,经过下列各步骤:Wherein the tofu glucoside is extracted and purified according to the following method, and undergoes the following steps:
(1)豆腐果种子粉碎,过100目筛,再加入体积浓度为70%的乙醇在25℃下冷浸40min,再超声波提取60min,过滤,滤液在45℃下进行旋转蒸发浓缩,回收乙醇,得到母猪果乙醇提取物;(1) Crush the bean curd seeds, pass through a 100-mesh sieve, then add ethanol with a volume concentration of 70% and soak for 40 minutes at 25°C, then ultrasonically extract for 60 minutes, filter, and the filtrate is concentrated by rotary evaporation at 45°C to recover ethanol. Obtain the ethanol extract of sow fruit;
(2)在步骤(1)所得豆腐果乙醇提取物中按固液比g/mL为5:25加入纯水进行溶解,上大孔树脂D101型,先用纯水洗脱除去多糖、蛋白质等水溶性杂质,再用体积浓度为50%的乙醇洗脱5个保留体积,收集大孔树脂体积浓度为30%的乙醇流出液,经减压浓缩,再加入浓缩物体积3倍的浓度为92%的乙醇,在3℃下静置20h以析出结晶,再抽滤出结晶,即得到豆腐果苷纯品。所得豆腐果苷纯度大于95%,豆腐果苷的得率为母猪果种子的1.06%。(2) Add pure water to the ethanol extract of bean curd fruit obtained in step (1) according to the solid-to-liquid ratio g/mL of 5:25 to dissolve, apply macroporous resin D101 type, and first elute with pure water to remove polysaccharides, proteins, etc. Water-soluble impurities, then elute 5 retention volumes with ethanol with a volume concentration of 50%, collect the ethanol effluent with a volume concentration of 30% of the macroporous resin, concentrate under reduced pressure, and then add the concentration of 3 times the volume of the concentrate to be 92 % ethanol, stand at 3°C for 20h to precipitate crystals, and then filter out the crystals to obtain pure tofu fruit glycosides. The purity of the obtained tofu glucoside is greater than 95%, and the yield of the tofu glucoside is 1.06% of that of sow fruit seeds.
其中薏苡仁内酯按下列方法提取纯化,经过下列各步骤:Among them, coix seed lactone is extracted and purified according to the following method, and undergoes the following steps:
将薏苡仁粉碎,过100目筛,再将薏苡仁粉在温度40℃、压力37MPa、CO2流量为15kg/h的条件下进行超临界二氧化碳萃取1h,采用体积浓度为70%的乙醇溶解萃取物质,再经旋转蒸发去除乙醇,得到黄色的油脂,即为薏苡仁内酯。所得薏苡仁内酯萃取得率为5.3%。Crush coix seed, pass it through a 100-mesh sieve, and then conduct supercritical carbon dioxide extraction for 1 h under the conditions of temperature 40°C, pressure 37 MPa, and CO 2 flow rate 15 kg/h, and use ethanol with a volume concentration of 70% to dissolve and extract substance, and then the ethanol was removed by rotary evaporation to obtain yellow oil, which was coix seed lactone. The extraction yield of coix seed lactone was 5.3%.
上述蒜头果神经酸、豆腐果苷、薏苡仁内酯提取物按比例充分混合,再加入药学上可接受的辅料制备成任何一种常用的胶囊剂。The above-mentioned allicin, tofu glucoside and coix seed lactone extracts are fully mixed in proportion, and then pharmaceutically acceptable auxiliary materials are added to prepare any commonly used capsules.
实施例2Example 2
治疗神经衰弱和预防老年痴呆症的药物组合物,由下列质量百分比的组分组成:The pharmaceutical composition for treating neurasthenia and preventing senile dementia consists of the following components in mass percentage:
蒜头果神经酸 1%、Garlic Nervous Acid 1%,
豆腐果苷 10%、Tofu glucoside 10%,
薏苡仁内酯 10%、Coix Seed Lactone 10%,
辅料 79%,Excipients 79%,
其中辅料为糊精、乳糖、羧甲基淀粉钠、微晶纤维素、淀粉、羟丙基纤维素。The auxiliary materials are dextrin, lactose, sodium carboxymethyl starch, microcrystalline cellulose, starch, and hydroxypropyl cellulose.
其中蒜头果神经酸按下列步骤进行提取、纯化:Wherein the garlic fruit nerve acid is extracted and purified according to the following steps:
(1)将蒜头果种子去外壳和表皮,按固液比g/mL为1:30,用3℃的浓度为20mM、pH=7.0的磷酸盐缓冲液进行捣碎后,再经超声波粉碎处理50min,于4℃下进行抽提过夜,然后用4层纱布过滤,再在4℃下以5000r/min的转速进行离心分离35min,重复两次,去除上清液得剩余物;其中磷酸盐缓冲液按下列操作配制:将浓度为0.2M的磷酸氢二钠溶液与浓度为0.2M磷酸二氢钠溶液按体积比为12.3:87.7混合,即得到pH=6.0的磷酸盐缓冲液;上清液经后续纯化分离得到蛋白质沉淀;(1) Remove the shell and epidermis of the garlic fruit seeds, according to the solid-to-liquid ratio g/mL of 1:30, mash with phosphate buffer solution with a concentration of 20mM and pH=7.0 at 3°C, and then ultrasonically pulverize 50min, extract overnight at 4°C, then filter with 4 layers of gauze, then centrifuge at 5000r/min at 4°C for 35min, repeat twice, remove the supernatant to obtain the residue; the phosphate buffer The solution is prepared according to the following operations: mix the disodium hydrogen phosphate solution with a concentration of 0.2M and the sodium dihydrogen phosphate solution with a concentration of 0.2M at a volume ratio of 12.3:87.7 to obtain a phosphate buffer solution with pH=6.0; the supernatant After subsequent purification and separation, protein precipitation is obtained;
(2)将步骤(1)所得剩余物按固液比g/mL=5:10加入石油醚进行搅拌,再静置分层,经过滤后收集滤液,再以滤液反复浸泡滤渣2次,每次浸泡30min后过滤,合并滤液,再在45℃下进行旋转蒸发以去除石油醚,得到淡黄色的蒜头果油;(2) Add petroleum ether to the residue obtained in step (1) according to the solid-to-liquid ratio g/mL=5:10 for stirring, then let it stand for stratification, collect the filtrate after filtration, and then soak the filter residue twice with the filtrate, each time After soaking for the first time for 30 minutes, filter, combine the filtrates, and then carry out rotary evaporation at 45°C to remove petroleum ether to obtain light yellow garlic fruit oil;
(3)按上样量:硅胶量=10:100的质量比称取粒度为250目的硅胶G,先按固液比g/mL=5:2加入石油醚溶解硅胶G,再搅拌20min后,将其倒入层析柱中,待硅胶层析柱不含有气泡,沉降稳定后,将步骤(2)所得蒜头果油按固液比g/mL=3:1加入石油醚溶解后,装入硅胶层析柱上层,采用石油醚-乙酸乙酯洗脱系统进行梯度洗脱,按溶解有蒜头果油的石油醚:乙酸乙酯=50:1(V/V)的馏分,于45℃以下对馏分进行减压浓缩,得到无色块状结晶,即为蒜头果神经酸。(3) Weigh the silica gel G with a particle size of 250 mesh according to the mass ratio of the sample amount: the amount of silica gel = 10:100, first add petroleum ether to dissolve the silica gel G according to the solid-liquid ratio g/mL=5:2, and then stir for 20 minutes. Pour it into the chromatographic column. After the silica gel chromatographic column does not contain air bubbles and the sedimentation is stable, the garlic fruit oil obtained in step (2) is dissolved in petroleum ether according to the solid-to-liquid ratio g/mL=3:1, and then put into The upper layer of the silica gel chromatography column is gradiently eluted with petroleum ether-ethyl acetate elution system, according to the fraction of petroleum ether dissolved with garlic fruit oil: ethyl acetate = 50:1 (V/V), at below 45°C Concentrate the fractions under reduced pressure to obtain colorless blocky crystals, which are allicin.
用薄层色谱法将神经酸标准品与该无色结晶在同一薄层板上点样,展开,进行比对,结果该无色结晶和神经酸标准品在同一薄层板的相同位置显示相同紫的斑点,并且在三种不同展开系统中均具有相同颜色斑点和相同Rf值,证明该无色结晶即为神经酸。此方法得到的神经酸含量大于95%。神经酸得率为蒜头果油的11.054%。The nervonic acid standard and the colorless crystal were spotted on the same thin-layer plate by thin-layer chromatography, developed, and compared. As a result, the colorless crystal and the nervonic acid standard showed the same color at the same position on the same thin-layer plate. Purple spots, and the same color spots and the same Rf value in three different unfolding systems, prove that the colorless crystal is nervonic acid. The content of nervous acid obtained by this method is greater than 95%. The yield of nervonic acid is 11.054% of that of garlic fruit oil.
其中豆腐果苷按下列方法提取纯化,经过下列各步骤:Wherein the tofu glucoside is extracted and purified according to the following method, and undergoes the following steps:
(1)豆腐果种子粉碎,过100目筛,再加入体积浓度为60%的乙醇在20℃下冷浸60min,再超声波提取45min,过滤,滤液在50℃下进行旋转蒸发浓缩,回收乙醇,得到母猪果乙醇提取物;(1) Crush the bean curd seeds, pass through a 100-mesh sieve, then add ethanol with a volume concentration of 60%, soak at 20°C for 60 minutes, then extract with ultrasonic waves for 45 minutes, filter, and the filtrate is concentrated by rotary evaporation at 50°C to recover ethanol. Obtain the ethanol extract of sow fruit;
(2)在步骤(1)所得豆腐果乙醇提取物中按固液比g/mL为3:19加入纯水进行溶解,上大孔树脂D101型,先用纯水洗脱除去多糖、蛋白质等水溶性杂质,再用体积浓度为40%的乙醇洗脱4个保留体积,收集大孔树脂体积浓度为40%的乙醇流出液,经减压浓缩,再加入浓缩物体积2倍的浓度为95%的乙醇,在4℃下静置24h以析出结晶,再抽滤出结晶,即得到豆腐果苷纯品。所得豆腐果苷纯度大于95%,豆腐果苷的得率为母猪果种子的1.57%。(2) Add pure water to the tofu fruit ethanol extract obtained in step (1) according to the solid-to-liquid ratio g/mL of 3:19 to dissolve, apply macroporous resin D101 type, and first elute with pure water to remove polysaccharides, proteins, etc. Water-soluble impurities, then elute 4 retention volumes with ethanol with a volume concentration of 40%, collect the ethanol effluent with a volume concentration of 40% of the macroporous resin, concentrate under reduced pressure, and then add the concentration of 2 times the volume of the concentrate to 95 % ethanol, stand at 4°C for 24 hours to precipitate crystals, and then filter out the crystals to obtain pure tofu fruit glycosides. The purity of the obtained tofu glucoside is greater than 95%, and the yield of the tofu glucoside is 1.57% of that of the sow fruit seeds.
其中薏苡仁内酯按下列方法提取纯化,经过下列各步骤:Among them, coix seed lactone is extracted and purified according to the following method, and undergoes the following steps:
将薏苡仁粉碎,过100目筛,再将薏苡仁粉在温度35℃、压力40MPa、CO2流量为10kg/h的条件下进行超临界二氧化碳萃取2h,采用体积浓度为85%的乙醇溶解萃取物质,再经旋转蒸发去除乙醇,得到黄色的油脂,即为薏苡仁内酯。所得薏苡仁内酯萃取得率为5.9%。Crush coix seed, pass it through a 100-mesh sieve, and then conduct supercritical carbon dioxide extraction for 2 hours under the conditions of temperature 35°C, pressure 40MPa, CO 2 flow rate 10kg/h, and use ethanol with a volume concentration of 85% to dissolve and extract substance, and then the ethanol was removed by rotary evaporation to obtain yellow oil, which was coix seed lactone. The obtained coix seed lactone extraction yield was 5.9%.
上述蒜头果神经酸、豆腐果苷、薏苡仁内酯提取物按比例充分混合,再加入药学上可接受的辅料制备成任何一种常用的颗粒剂、丸剂或片剂。The above-mentioned allicin, tofu glucoside and coix seed lactone extracts are fully mixed in proportion, and then pharmaceutically acceptable auxiliary materials are added to prepare any commonly used granules, pills or tablets.
实施例3Example 3
治疗神经衰弱和预防老年痴呆症的药物组合物,由下列质量百分比的组分组成:The pharmaceutical composition for treating neurasthenia and preventing senile dementia consists of the following components in mass percentage:
蒜头果神经酸 10%、Garlic Nervous Acid 10%,
豆腐果苷 1%、Tofu glucoside 1%,
薏苡仁内酯 1%、Coixenolide 1%,
辅料 88%,Excipients 88%,
其中辅料为糊精、乳糖、羧甲基淀粉钠、微晶纤维素、淀粉、羟丙基纤维素。The auxiliary materials are dextrin, lactose, sodium carboxymethyl starch, microcrystalline cellulose, starch, and hydroxypropyl cellulose.
其中蒜头果神经酸按下列步骤进行提取、纯化:Wherein the garlic fruit nerve acid is extracted and purified according to the following steps:
(1)将蒜头果种子去外壳和表皮,按固液比g/mL为8:5,用4℃的浓度为20mM、pH=7.0的磷酸盐缓冲液进行捣碎后,再经超声波粉碎处理30min,于4℃下进行抽提过夜,然后用4层纱布过滤,再在4℃下以8000 r/min的转速进行离心分离30min,重复两次,去除上清液得剩余物;其中磷酸盐缓冲液按下列操作配制:将浓度为0.2M的磷酸氢二钠溶液与浓度为0.2M磷酸二氢钠溶液按体积比为46:68混合,即得到pH=7.0的磷酸盐缓冲液;上清液经后续纯化分离得到蛋白质沉淀;(1) Remove the shell and epidermis of the garlic fruit seeds, according to the solid-to-liquid ratio g/mL of 8:5, mash with phosphate buffer solution with a concentration of 20mM and pH=7.0 at 4°C, and then ultrasonically pulverize 30min, extract overnight at 4°C, then filter with 4 layers of gauze, then centrifuge at 8000 r/min at 4°C for 30min, repeat twice, remove the supernatant to obtain the residue; The buffer solution is prepared according to the following operations: mix the disodium hydrogen phosphate solution with a concentration of 0.2M and the sodium dihydrogen phosphate solution with a concentration of 0.2M at a volume ratio of 46:68 to obtain a phosphate buffer solution with pH=7.0; the supernatant The solution was purified and separated to obtain protein precipitation;
(2)将步骤(1)所得剩余物按固液比g/mL=1:5加入石油醚进行搅拌,再静置分层,经过滤后收集滤液,再以滤液反复浸泡滤渣3次,每次浸泡60min后过滤,合并滤液,再在50℃下进行旋转蒸发以去除石油醚,得到淡黄色的蒜头果油;(2) Add petroleum ether to the residue obtained in step (1) according to the solid-to-liquid ratio g/mL=1:5 for stirring, then let it stand for stratification, collect the filtrate after filtration, and soak the filter residue 3 times with the filtrate repeatedly, each Filter after soaking for 60 minutes for the first time, combine the filtrates, and then carry out rotary evaporation at 50°C to remove petroleum ether to obtain light yellow garlic fruit oil;
(3)按上样量:硅胶量=1:10的质量比称取粒度为200目的硅胶G,先按固液比g/mL=1:10加入石油醚溶解硅胶G,再搅拌30min后,将其倒入层析柱中,待硅胶层析柱不含有气泡,沉降稳定后,将步骤(2)所得蒜头果油按固液比g/mL=1:8加入石油醚溶解后,装入硅胶层析柱上层,采用石油醚-乙酸乙酯洗脱系统进行梯度洗脱,按溶解有蒜头果油的石油醚:乙酸乙酯=30:1(V/V)的馏分,于40℃以下对馏分进行减压浓缩,得到无色块状结晶,即为蒜头果神经酸。(3) Weigh the silica gel G with a particle size of 200 mesh according to the mass ratio of the sample amount: the amount of silica gel = 1:10, first add petroleum ether to dissolve the silica gel G according to the solid-liquid ratio g/mL=1:10, and then stir for 30 minutes. Pour it into the chromatographic column. After the silica gel chromatographic column does not contain air bubbles and the sedimentation is stable, the garlic fruit oil obtained in step (2) is dissolved in petroleum ether according to the solid-to-liquid ratio g/mL=1:8, and then loaded into The upper layer of the silica gel chromatography column is gradiently eluted with petroleum ether-ethyl acetate elution system, according to the fraction of petroleum ether dissolved with garlic fruit oil:ethyl acetate=30:1 (V/V), at below 40°C Concentrate the fractions under reduced pressure to obtain colorless blocky crystals, which are allicin.
用薄层色谱法将神经酸标准品与该无色结晶在同一薄层板上点样,展开,进行比对,结果该无色结晶和神经酸标准品在同一薄层板的相同位置显示相同紫的斑点,并且在三种不同展开系统中均具有相同颜色斑点和相同Rf值,证明该无色结晶即为神经酸。此方法得到的神经酸含量大于95%。神经酸得率为蒜头果油的10.819%。The nervonic acid standard and the colorless crystal were spotted on the same thin-layer plate by thin-layer chromatography, developed, and compared. As a result, the colorless crystal and the nervonic acid standard showed the same color at the same position on the same thin-layer plate. Purple spots, and the same color spots and the same Rf value in three different unfolding systems, prove that the colorless crystal is nervonic acid. The content of nervous acid obtained by this method is greater than 95%. The yield of nervonic acid is 10.819% of that of garlic fruit oil.
其中豆腐果苷按下列方法提取纯化,经过下列各步骤:Wherein the tofu glucoside is extracted and purified according to the following method, and undergoes the following steps:
(1)豆腐果种子粉碎,过100目筛,再加入体积浓度为50%的乙醇在30℃下冷浸30min,再超声波提取30min,过滤,滤液在55℃下进行旋转蒸发浓缩,回收乙醇,得到母猪果乙醇提取物;(1) Crush the bean curd seeds, pass through a 100-mesh sieve, then add ethanol with a volume concentration of 50%, soak for 30 minutes at 30°C, then extract with ultrasonic waves for 30 minutes, filter, and concentrate the filtrate by rotary evaporation at 55°C to recover ethanol. Obtain the ethanol extract of sow fruit;
(2)在步骤(1)所得豆腐果乙醇提取物中按固液比g/mL为1:5加入纯水进行溶解,上大孔树脂D101型,先用纯水洗脱除去多糖、蛋白质等水溶性杂质,再用体积浓度为30%的乙醇洗脱4个保留体积,收集大孔树脂体积浓度为50%的乙醇流出液,经减压浓缩,再加入浓缩物体积2倍的浓度为90%的乙醇,在4℃下静置12h以析出结晶,再抽滤出结晶,即得到豆腐果苷纯品。所得豆腐果苷纯度大于95%,豆腐果苷的得率为母猪果种子的1.13%。(2) Add pure water to the tofu fruit ethanol extract obtained in step (1) according to the solid-to-liquid ratio g/mL of 1:5 to dissolve, apply macroporous resin D101 type, and first elute with pure water to remove polysaccharides, proteins, etc. Water-soluble impurities, then elute 4 retention volumes with ethanol with a volume concentration of 30%, collect the ethanol effluent with a volume concentration of 50% of the macroporous resin, concentrate under reduced pressure, and then add 2 times the volume of the concentrate to a concentration of 90 % ethanol, stand at 4°C for 12 hours to precipitate crystals, and then filter out the crystals to obtain pure tofu fruit glycosides. The purity of the obtained tofu glucoside is greater than 95%, and the yield of the tofu glucoside is 1.13% of that of the sow fruit seeds.
其中薏苡仁内酯按下列方法提取纯化,经过下列各步骤:Among them, coix seed lactone is extracted and purified according to the following method, and undergoes the following steps:
将薏苡仁粉碎,过100目筛,再将薏苡仁粉在温度38℃、压力38MPa、CO2流量为20kg/h的条件下进行超临界二氧化碳萃取1.5h,采用体积浓度为95%的乙醇溶解萃取物质,再经旋转蒸发去除乙醇,得到黄色的油脂,即为薏苡仁内酯。所得薏苡仁内酯萃取得率为5.77%。Crush coix seed, pass it through a 100-mesh sieve, then extract coix seed powder with supercritical carbon dioxide for 1.5 h at a temperature of 38°C, a pressure of 38 MPa, and a CO flow rate of 20 kg/h, and dissolve it in ethanol with a volume concentration of 95%. Extract the substance, and then remove the ethanol by rotary evaporation to obtain a yellow oil, which is coix seed lactone. The extraction yield of coix seed lactone was 5.77%.
上述蒜头果神经酸、豆腐果苷、薏苡仁内酯提取物按比例充分混合,再加入药学上可接受的辅料制备成任何一种常用的口服液。The above-mentioned allicin, tofu glucoside and coix seed lactone extracts are fully mixed in proportion, and then pharmaceutically acceptable auxiliary materials are added to prepare any commonly used oral liquid.
取上述实施例所得治疗神经衰弱和预防老年痴呆症的药物组合物,用于下列临床治疗:Get the pharmaceutical composition of above-mentioned embodiment gained treatment neurasthenia and prevention senile dementia, be used for following clinical treatment:
一、治疗对象1. Subjects of treatment
神经衰弱患者的30例;老年痴呆症患者的30例;抑郁症患者的50例。30 cases of neurasthenia patients; 30 cases of senile dementia patients; 50 cases of depression patients.
将上述各类病例随机平分为治疗组和对照组各55例。The above-mentioned cases were randomly divided into treatment group and control group, 55 cases in each group.
二、用法Two, usage
治疗组服用上述实施例所得治疗神经衰弱和预防老年痴呆症的药物组合物,一次2g,一日1次,连服30日进行观察。The treatment group took the pharmaceutical composition for treating neurasthenia and preventing senile dementia obtained in the above examples, 2 g each time, once a day, for 30 consecutive days for observation.
对照组中服用市购神衰康胶囊,一日数次,一次5粒,一日2次,连服30日进行观察。The control group took commercially available Shenshuaikang capsules, several times a day, 5 capsules each time, twice a day, for 30 consecutive days for observation.
三、结果3. Results
本发明提供的治疗神经衰弱和预防老年痴呆症的药物组合物临床治疗效果:显效率达100%,对神经衰弱患者症状有效率达83%;对老年痴呆症患者症状有效率达78%;对抑郁症患者症状有效率达90%。The clinical therapeutic effects of the pharmaceutical composition for treating neurasthenia and preventing senile dementia provided by the present invention: the effective rate reaches 100%, and the effective rate reaches 83% for the symptoms of neurasthenia patients; the effective rate for the symptoms of senile dementia patients reaches 78%; The effective rate of symptoms in patients with depression is as high as 90%.
而对照组对神经衰弱患者症状有效率达75%;对老年痴呆症患者症状有效率达65%;对抑郁症患者症状有效率达43%。The control group has an effective rate of 75% for the symptoms of neurasthenia; 65% for the symptoms of Alzheimer's patients; and 43% for the symptoms of depression patients.
四、结论4. Conclusion
本发明提供的治疗神经衰弱和预防老年痴呆症的药物组合物是由蒜头果神经酸、豆腐果苷、薏苡仁内酯提取物等组成的组合物,对抗老年痴呆、神经衰弱、抗肿瘤有显著疗效,其作用优于对照组。The pharmaceutical composition for treating neurasthenia and preventing senile dementia provided by the present invention is a composition composed of allicin, tofu glucoside, coix seed lactone extract, etc., and has significant anti-senile dementia, neurasthenia and anti-tumor effects. Curative effect, its effect is better than that of the control group.
该治疗神经衰弱和预防老年痴呆症的药物组合物完全利用植物提取纯化,原料易获得,有疗效好、应用安全、毒副作用小等优点,所制得的产品质量稳定,使用方便,更适合于临床用药,无任何副作用,疗效显著。The pharmaceutical composition for treating neurasthenia and preventing senile dementia is completely extracted and purified from plants, the raw materials are easy to obtain, and has the advantages of good curative effect, safe application, and small toxic and side effects. The prepared product is stable in quality and easy to use, and is more suitable for Clinical medication, without any side effects, the curative effect is remarkable.
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410551879.9A CN104258193B (en) | 2014-10-17 | 2014-10-17 | A kind of pharmaceutical composition for treating neurasthenia and prevention senile dementia |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410551879.9A CN104258193B (en) | 2014-10-17 | 2014-10-17 | A kind of pharmaceutical composition for treating neurasthenia and prevention senile dementia |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104258193A CN104258193A (en) | 2015-01-07 |
CN104258193B true CN104258193B (en) | 2017-09-15 |
Family
ID=52149850
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410551879.9A Active CN104258193B (en) | 2014-10-17 | 2014-10-17 | A kind of pharmaceutical composition for treating neurasthenia and prevention senile dementia |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104258193B (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105037448B (en) * | 2015-09-10 | 2017-09-15 | 福建农林大学 | A kind of method that rapid, high volume extracts the separation oligomeric sugar monomer of coix seed |
CN105853996A (en) * | 2016-03-31 | 2016-08-17 | 山东健科生物技术有限公司 | A cranial nerve activating and restoring liquid |
CN106376933A (en) * | 2016-08-30 | 2017-02-08 | 昆明酷特利生物科技有限公司 | Brain-invigorating antioxidant health product and applications thereof |
CN107594268A (en) * | 2017-08-04 | 2018-01-19 | 杨宇明 | A kind of invigorating brain and relieving mental uneasiness nervonic acid compound beverage antianxity and preparation method thereof |
CN107875369A (en) * | 2017-12-19 | 2018-04-06 | 北京昆达中医医学研究院 | A kind of Chinese medicine natural drug for treating senile dementia |
CN108467345B (en) * | 2018-04-10 | 2021-03-09 | 大理大学 | Method for extracting nervonic acid from garlic fruits and nervonic acid clathrate compound |
CN111117773B (en) * | 2019-12-25 | 2022-12-09 | 昆明酷特利生物科技有限公司 | Method for separating nervonic acid from garlic oil and application thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102824353A (en) * | 2011-06-14 | 2012-12-19 | 上海现代药物制剂工程研究中心有限公司 | Helicid oral preparation, and preparation method and application thereof |
-
2014
- 2014-10-17 CN CN201410551879.9A patent/CN104258193B/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102824353A (en) * | 2011-06-14 | 2012-12-19 | 上海现代药物制剂工程研究中心有限公司 | Helicid oral preparation, and preparation method and application thereof |
Non-Patent Citations (2)
Title |
---|
中国含神经酸植物开发利用研究;王性炎等;《中国油脂》;20061231;第31卷(第03期);69-71 * |
薏苡仁油抗肿瘤作用研究;陆蕴等;《中药药理与临床》;19991231;第15卷(第06期);21-23 * |
Also Published As
Publication number | Publication date |
---|---|
CN104258193A (en) | 2015-01-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104258193B (en) | A kind of pharmaceutical composition for treating neurasthenia and prevention senile dementia | |
CN101463061B (en) | Ginseng saponin Rg1 and Rb1 in pseudo-ginseng and preparation of total saponin thereof | |
CN102030834B (en) | Method for extracting and preparing camellia polysaccharide from camellia and application of camellia polysaccharide | |
CN112870236B (en) | Flavone effective part of abelmoschus manihot and preparation method and application thereof | |
CN101085728A (en) | Method for preparing paeonol and paeoniflorin from cortex moutan | |
CN101129475A (en) | Extractive of humulus plants, its use and pharmaceutical composition containing the extractive | |
CN102670764A (en) | Active parts of wild jujube as well as preparation method and application thereof | |
CN101229335A (en) | Method for Enzymatically Preparing Smilax Smilax Total Saponins Extract | |
CN103169788A (en) | Chinese date leaf extractive and application thereof in preparation of medicament or health food for preventing and treating liver injury | |
CN110496157B (en) | Safflower Xiaoyao preparation for treating breast cancer and preparation method and application thereof | |
CN102973719A (en) | Traditional Chinese medicine health-care food with bowel relaxing function and preparation method thereof | |
CN112107639B (en) | Application of fructus viticis extract in preparation of antidepressant drugs | |
CN101926869B (en) | Medicament for treating dizziness and headache and preparation method thereof | |
CN111117773A (en) | Method for separating nervonic acid from garlic oil and application thereof | |
CN101549010B (en) | A preparing method and application of malaytea scurfpea fruit total glycosides extract | |
CN103059008A (en) | Method for simultaneously preparing high-purity puerarin and daidzein | |
CN105998104B (en) | A kind of purposes of fruits of elm extract in terms of nerve protection medicine is treated in preparation | |
CN101023979A (en) | Lamiophlomis-rotata leaf-stem distract and its preparing process and use | |
CN100428942C (en) | Heart-nourishing and nerve-soothing medicine and preparation method thereof | |
CN103301256A (en) | Preparation method of medicinal plant extract being capable of reducing blood fat and application thereof in pharmacy and health food | |
CN102579869A (en) | Preparation method of traditional Tibetan medicine composition for treating liver diseases | |
CN113413413A (en) | Preparation method and quality detection method of traditional Chinese medicine composition for treating cerebrovascular diseases through meridian rehabilitation method | |
CN102558128A (en) | Extract containing prodelphinidin and procyanidin of ginkgo and its preparation method and application | |
CN1806831B (en) | A kind of medicine for treating psoriasis and preparation method thereof | |
CN102309622B (en) | Application of total verbena glycosides in the preparation of drugs for preventing and treating cerebral ischemia |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |